A randomized, multi-center phase III trial of adjuvant chemotherapy with gemcitabine and capecitabine (GemCap) compared to capecitabine (Cap) alone in curatively resected biliary tract cancer (BilGemCap Study): KCSG HB20-14.

被引：0

作者：

Park, Joon Oh

Park, Joon Seong

Lee, Choong-kun

Chon, Hong Jae

Choi, Sae Byeol

Hwang, Dae Wook

Oh, Do-Youn

Lee, Myung Ah

Jang, Jin-Young

Ryoo, Baek-Yeol

机构：

[1] Samsung Med Ctr, Seoul, South Korea

[2] Yonesi Univ, Gangnam Severance Hosp, Seoul, South Korea

[3] Yonsei Univ, Coll Med, Dept Internal Med, Div Med Oncol,Yonsei Canc Ctr, Seoul, South Korea

[4] CHA Univ, Sch Med, Dept Med Oncol, CHA Bundang Med Ctr, Seongnam, South Korea

[5] Korea Univ, Guro Hosp, Seoul, South Korea

[6] Asan Med Ctr, Seoul, South Korea

[7] Seoul Natl Univ Hosp, Seoul, South Korea

[8] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea

[9] Seoul Natl Univ, Coll Med, Dept Surg, Div Hepatobiliary & Pancreat Surg, Seoul, South Korea

[10] Univ Ulsan, Coll Med, Dept Oncol, Asan Med Ctr, Seoul, South Korea

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS633

引用

页码：TPS633 / TPS633

页数：1

共 12 条

[1] A randomized phase III study of adjuvant capecitabine vs observation in curatively resected stage IB (by AJCC 6th edition) gastric cancer (CATALYSIS; KCSG ST14-05).
Ryu, Min-Hee
Cho, Jae Yong
Zang, Dae Young
Lee, Woon Kee
Lee, Keun-Wook
Shin, Dong Bok
Nam, Byung-Ho
Lee, Sung Sook
Lee, Hyun Woo
Kim, Jong Gwang
Kim, Jin-Soo
Hwang, In Gyu
Baek, Jin Ho
Yoo, Chang Hak
Kang, Yoon-Koo
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[2] BILCAP: A randomized clinical trial evaluating adjuvant chemotherapy with capecitabine compared to expectant treatment alone following curative surgery for biliary tract cancer.
Bridgewater, J. A.
Stubbs, C.
Primrose, J. N.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[3] ESPAC-4: A Multicenter, International, Randomized Controlled Phase III Trial of Adjuvant Combination Chemotherapy of Gemcitabine (GEM) and Capecitabine (CAP), Versus Monotherapy Gemcitabine in Patients With Resected Pancreatic Ductal Adenocarcinoma
Neoptolemos, J. P.
Palmer, D.
Ghaneh, P.
Valle, J.
Cunningham, D.
Wadsley, J.
Meyer, T.
Anthoney, A.
Glimelius, B.
Falk, S.
Lind, P.
Izbicki, J.
Middleton, G.
Ross, P.
Wasan, H.
McDonald, A.
Crosby, T.
Psarelli, E.
Hammel, P.
Buechler, M. W.
PANCREAS, 2016, 45 (10) : 1529 - 1529
[4] A multi-center, open-label, randomized phase III trial of first-line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer
Hwang, In Gyu
Ji, Yin Ho
Kang, Jung Hun
Lee, Hyo Rak
Lee, Hui-Young
Chi, Kyong-Choun
Park, Suk Won
Lee, Su Jin
Kim, Seung Tae
Lee, Jeeyun
Park, Se Hoon
Park, Joon Oh
Park, Young Suk
Lim, Ho Yeong
Kang, Won Ki
JOURNAL OF GERIATRIC ONCOLOGY, 2017, 8 (03) : 170 - 175
[5] ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma.
Neoptolemos, John P.
Palmer, Dan
Ghaneh, Paula
Valle, Juan W.
Cunningham, David
Wadsley, Jonathan
Meyer, Tim
Anthoney, Alan
Glimelius, Bengt
Falk, Stephen
Segersvard, Ralf
Izbicki, Jakob R.
Middleton, Gary William
Ross, Paul J.
Wasan, Harpreet
Mcdonald, Alec
Crosby, Tom David Lewis
Psarelli, Eftychia Eirini
Hammel, Pascal
Buchler, Markus W.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (18)
[6] A randomized phase II trial of adjuvant chemotherapy with S-1 versus S-1 and gemcitabine (GS) versus gemcitabine alone (GEM) in patients with resected pancreatic cancer (CAP-002 study).
Yoshitomi, Hideyuki
Shimizu, Hiroaki
Yoshidome, Hiroyuki
Ohtsuka, Masayuki
Kato, Atsushi
Furukawa, Katsunori
Takayashiki, Tsukasa
Kuboki, Satoshi
Okamura, Daiki
Suzuki, Daisuke
Nakajima, Masayuki
Aida, Toshiaki
Miyazaki, Masaru
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[7] ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma: Five year follow-up.
Neoptolemos, John P.
Palmer, Daniel H.
Ghaneh, Paula
Valle, Juan W.
Cunningham, David
Wadsley, Jonathan
Meyer, Tim
Anthoney, Alan
Glimelius, Bengt
Falk, Stephen
Segersvard, Ralf
Middleton, Gary William
Ross, Paul J.
Wasan, Harpreet Singh
McDonald, Alec
Crosby, Tom David Lewis
Psarelli, Eftychia Eirini
Hammel, Pascal
Hackert, Thilo
Buchler, Markus W.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[8] Trastuzumab plus FOLFOX for gemcitabine/cisplatin refractory HER2-positive biliary tract cancer: A multi-institutional phase II trial of the Korean Cancer Study Group (KCSG-HB19-14).
Lee, Choong-Kun
Chon, Hong Jae
Cheon, Jaekyung
Lee, Myung Ah
Im, Hyeon-Su
Jang, Joung-Soon
Kim, Min Hwan
Ock, Chan-Young
Kim, Jin Won
Park, Hyung Soon
Kang, Myoung Joo
Choi, Hye Jin
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[9] Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi- institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14)
Lee, Choong-kun
Chon, Hong Jae
Cheon, Jaekyung
Lee, Myung Ah
Im, Hyeon-Su
Jang, Joung-Soon
Kim, Min Hwan
Park, Sejung
Kang, Beodeul
Hong, Moonki
Kim, Jin Won
Park, Hyung Soon
Kang, Myoung Joo
Park, Young Nyun
Choi, Hye Jin
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2023, 8 (01): : 56 - 65
[10] A randomized phase III study comparing S-1 plus docetaxel with S-1 alone as a postoperative adjuvant chemotherapy for curatively resected stage III gastric cancer (JACCRO GC-07 trial).
Kodera, Yasuhiro
Yoshida, Kazuhiro
Kochi, Mitsugu
Ichikawa, Wataru
Kakeji, Yoshihiro
Sano, Takeshi
Nagao, Narutoshi
Takahashi, Masazumi
Takagane, Akinori
Nakamura, Masanori
Kaji, Masahide
Okitsu, Hiroshi
Nomura, Takashi
Matsui, Takanori
Yoshikawa, Takaki
Matsuyama, Jin
Yamada, Makoto
Ito, Yuichi
Takeuchi, Masahiro
Fujii, Masashi
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

← 1 2 →